Medical Licensing (MD/DO) · Independent exam preparation
Medical Oncology Certification Examination Study Guide
Study biomarker-guided treatment, disease classification, supportive care, and trial interpretation through 60 focused concepts, 20 clinical questions, and 20 flashcards.
By CertMedbry · Updated 18 October 2026
Learn to distinguish actionable biomarkers, recognize treatment-defining disease features, manage common complications, and interpret clinical trials. This selective guide covers all ten certification domains. The official January 2026 blueprint and expanded certification outline define the full examination scope, including numerous topics beyond these 60 concepts.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which examination and pathway does this guide address?
The Medical Oncology Certification Examination administered by the American Board of Internal Medicine. The listing label 'ABIM - Subspecialty in Medical Oncology' refers to this examination. Traditional Maintenance of Certification and the Longitudinal Knowledge Assessment are separate assessment pathways.
Register, Prepare and Take Your Subspecialty Certification Exam: Medical Oncology · ABIM Expanded Blueprints
Which blueprint applies beginning in fall 2026?
Use the January 2026 certification blueprint and current expanded certification outline. ABIM's implementation schedule places expanded-blueprint publication in January 2026, LKA implementation in July 2026, and certification/traditional MOC implementation in fall 2026.
Medical Oncology Blueprint for Certification Examination — January 2026 · ABIM Expanded Blueprints · Medical Oncology Certification Examination Expanded Blueprint
How is the examination delivered?
The examination is delivered at a testing center in four multiple-choice sessions. Most questions present patient scenarios. Supporting material may include photographs, radiographs, CT or MRI images, photomicrographs, pedigrees, nomograms, and equianalgesic tables. ABIM's examination tutorial explains the presentation and controls.
Register, Prepare and Take Your Subspecialty Certification Exam: Medical Oncology · Medical Oncology Blueprint for Certification Examination — January 2026
How are the ten domains weighted?
Clinical Research Methodology and Ethics 6.5%; Palliative Care, Survivorship, and Oncologic Complications 11%; Hematologic Neoplasms 13%; Thoracic Cancer 11.5%; Breast Cancer 13.5%; Genitourinary Cancer 12%; Gynecologic Cancer 5.5%; Gastrointestinal Cancer 13.5%; Skin Cancer, Sarcomas, and Unknown Primary Site 7%; Head, Neck, Thyroid, and Central Nervous System Malignancies 6.5%. The summary table calls the 11% category 'Palliative Care, Survivorship, and Communication'; the detailed outline uses the domain name shown here.
Medical Oncology Blueprint for Certification Examination — January 2026 · Medical Oncology Certification Examination Expanded Blueprint
Which physician tasks receive the greatest emphasis?
ABIM assigns 60% to treatment/care decisions, 25% to diagnosis/testing, 10% to risk assessment/prognosis/epidemiology, and 5% to pathophysiology/basic science. Health equity spans content areas, including language barriers, health literacy, food insecurity, and financial barriers affecting care.
Medical Oncology Blueprint for Certification Examination — January 2026
How should the practice questions and flashcards be used?
Use them to identify reasoning errors and strengthen recall. Each 20-item set includes 1 research item, 2 supportive-care items, 3 hematologic items, 2 thoracic items, 3 breast items, 2 genitourinary items, 1 gynecologic item, 3 gastrointestinal items, 2 skin/sarcoma items, and 1 head/neck/thyroid/CNS item. This approximates domain weighting while covering every domain; it is not a full examination simulation or a prediction of passing.
Medical Oncology Blueprint for Certification Examination — January 2026
This guide addresses ABIM's Medical Oncology Certification Examination. It provides independent education for physician subspecialty board certification and contains original practice exercises. It is not an official ABIM question bank or a general medical licensure examination.
Outline used: January 2026 ABIM Medical Oncology Certification Examination blueprint, with the current expanded CERT outline; implemented for fall 2026 certification examinations. Verified on 2026-10-09. The workbook label 'ABIM - Subspecialty in Medical Oncology' maps to this official examination; the assigned slug is preserved.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Clinical Research Methodology and Ethics6.5%
1.Why does random allocation improve a treatment comparison?
Random allocation assigns treatment by chance rather than clinician or patient preference. It reduces systematic differences in prognostic factors between groups, including factors investigators did not measure. The resulting comparison can more credibly attribute outcome differences to treatment. Randomization does not guarantee identical baseline characteristics in a particular trial, especially a small one; chance imbalances remain possible.
Apply it
A small randomized trial has more patients with liver metastases in one group. Evaluate the allocation process and the imbalance's prognostic implications rather than assuming that randomization was manipulated.
Common pitfall: Matching measured characteristics is not equivalent to randomization. An apparently balanced observational comparison can still differ in unmeasured factors that influence both treatment selection and outcomes.
2.What different questions do response rate and duration of response answer?
Objective response rate describes the proportion of patients achieving a defined complete or partial tumor response. Duration of response describes how long a response lasts among responders. These endpoints address how frequently measurable shrinkage occurs and how durable that shrinkage is. Neither alone establishes an overall-survival benefit. Response criteria, confirmation requirements, and independent assessment help make the measurements interpretable.
Apply it
The FDA-described KRYSTAL-1 cohort had a confirmed response rate of 34% and median response duration of 5.8 months. Explain that duration applies to responders rather than every treated patient.
Common pitfall: Median response duration is not median survival. It also does not describe the experience of patients who never achieved an objective response.
3.What can a single-arm response study establish about comparative benefit?
A single-arm study can demonstrate antitumor activity and estimate response frequency and durability in its enrolled population. Without a concurrent randomized comparator, it cannot directly establish superiority over another regimen. Differences from historical cohorts may reflect eligibility, prognosis, previous treatment, or assessment practices. A confidence interval expresses uncertainty around an estimate; it does not remove selection bias or supply a missing comparison group.
Apply it
KRYSTAL-1 reported a 34% response rate with a 95% confidence interval of 25% to 45% in 94 patients. Interpret this as evidence of activity in that treatment setting.
Common pitfall: A numerically higher response rate than a separate historical study does not prove superior survival, better tolerability, or greater comparative effectiveness.
FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C-mutated colorectal cancer | FDA · NCI: Clinical Trial Randomization
4.How should random assignment be explained during consent?
Participants should understand that chance determines assignment among the trial's treatment groups. Explain the groups, the actual comparator, and the uncertainty motivating the trial in understandable language. A control group may receive standard treatment; control does not automatically mean placebo or absence of cancer care. Ask the participant to describe how assignment occurs and clarify that experimental status does not establish superiority.
Apply it
After an interpreter-assisted discussion, a patient says the oncologist will select the newest treatment. Revisit random assignment and check understanding before considering the consent discussion complete.
Common pitfall: A signature does not resolve therapeutic misconception. Correct the specific misunderstanding rather than merely repeating technical terminology or assuming that willingness to enroll proves comprehension.
NCI: Clinical Trial Randomization · Understanding Cancer Research Consent Forms - NCI
Palliative Care, Survivorship, and Oncologic Complications11%
5.Why should constipation prevention accompany opioid initiation?
Opioids reduce gastrointestinal propulsion and secretion, making constipation a predictable adverse effect. Tolerance to this bowel effect is limited, so a preventive bowel regimen is usually needed when ongoing opioid treatment begins. A stimulant laxative, with an osmotic agent when appropriate, addresses impaired motility more effectively than a stool softener alone. Suspected obstruction or impaction requires assessment before simply escalating laxatives.
Apply it
A patient starting scheduled morphine has normal bowel movements and no obstruction symptoms. Begin an appropriate preventive regimen and establish follow-up for stool frequency, consistency, and difficulty.
Common pitfall: Waiting for severe constipation creates avoidable morbidity. Dietary fiber or a stool softener alone may not adequately address opioid-related impairment of intestinal movement.
6.How does breakthrough pain differ from uncontrolled baseline pain?
Breakthrough pain is a transient exacerbation despite otherwise controlled background pain. Immediate-release rescue medication can address these episodes, whereas persistent pain throughout the dosing interval suggests that the baseline regimen needs reassessment. Frequent rescue use should prompt review of pain mechanism, adherence, timing, and adverse effects. Predictable movement-related or procedural pain may require anticipatory treatment rather than indiscriminate escalation of a long-acting opioid.
Apply it
A patient is comfortable at rest but develops severe pain during dressing changes. Characterize the trigger, assess the wound, and plan analgesia around the procedure.
Common pitfall: Increasing long-acting medication for brief predictable episodes can cause sedation between episodes while failing to match the timing of the actual pain.
7.Which findings make metastatic spinal cord compression an emergency?
New back pain with progressive leg weakness, gait impairment, sensory change, or bladder dysfunction in a patient with cancer raises concern for metastatic spinal cord compression. Arrange emergency assessment and urgent spinal imaging. In prostate cancer with cord compression, immediate corticosteroids and assessment for spinal surgery are important; radiation may follow surgery or provide definitive local treatment when surgery is unsuitable.
Apply it
A patient with metastatic prostate cancer develops back pain, bilateral leg weakness, and urinary retention. Activate emergency evaluation and urgent multidisciplinary treatment planning.
Common pitfall: Treating progressive weakness as routine painful bone metastasis can permit irreversible neurologic injury. Analgesia should accompany urgent investigation and treatment rather than delay them.
8.When can palliative care accompany active cancer treatment?
Palliative care addresses symptoms, distress, communication, and support for patients and families at any stage of serious illness. It can accompany cancer-directed treatment, including treatment intended to prolong life. Referral follows need rather than a requirement to stop systemic therapy. Hospice is a distinct model focused on care near the end of life; confusing the two can delay useful support during active treatment.
Apply it
A patient starting treatment for metastatic cancer has dyspnea, insomnia, and family distress. Add palliative care while anticancer therapy proceeds.
Common pitfall: Presenting palliative care only after all anticancer options are exhausted makes symptom support unnecessarily contingent on treatment failure and may discourage acceptance of helpful services.
9.How should goals of care guide treatment decisions?
Goals-of-care discussions connect medical options with what matters to the patient. Establish understanding, explain likely benefits and burdens, explore priorities, and recommend a plan consistent with those priorities. Preferences may change as disease and function change. Wanting to remain alert at home, for example, has practical implications for treatments requiring frequent hospitalization. Explain uncertainty honestly without presenting an individual survival estimate as certainty.
Apply it
A patient with progressive cancer prioritizes attending a family event and avoiding hospitalization. Compare another treatment line with symptom-focused care in terms of those specific priorities.
Common pitfall: A preference recorded months earlier may no longer fit current circumstances. Revisit goals after major progression, functional decline, or a meaningful change in treatment options.
10.When should fertility preservation be discussed?
Discuss reproductive effects before treatment that may impair fertility, when preservation options are most actionable. Risk depends on treatment, reproductive organs exposed, age, and baseline function. Prompt referral permits consideration of embryo or oocyte cryopreservation when appropriate. Counseling should address uncertainty and timing constraints. Relationship status or existing children does not establish whether future fertility matters to an individual patient.
Apply it
A young adult wants future pregnancy and is scheduled for potentially gonadotoxic therapy. Arrange an urgent reproductive-specialist discussion, coordinating preservation options with the oncology team's assessment of treatment urgency.
Common pitfall: Waiting until amenorrhea develops can close preservation opportunities. Menstrual status alone cannot reliably establish preserved fertility or permanent infertility.
11.How does ovarian transposition differ from gamete preservation?
Ovarian transposition moves ovaries away from an anticipated pelvic radiation field to reduce exposure. It does not store gametes and does not protect against systemic chemotherapy's gonadotoxic effects. Embryo or oocyte cryopreservation instead preserves reproductive material for possible later use. Strategy depends on treatment and reproductive goals. Scatter radiation and vascular effects mean that ovarian function is not guaranteed after transposition.
Apply it
A patient asks whether moving the ovaries will protect them from both pelvic radiation and chemotherapy. Explain the different exposures and assess whether additional preservation approaches are feasible.
Common pitfall: Fertility-preservation procedures are not interchangeable. Moving an ovary outside a radiation field does not remove its exposure to circulating chemotherapy or ensure future pregnancy.
Hematologic Neoplasms13%
12.When is observation appropriate for newly diagnosed CLL?
Asymptomatic chronic lymphocytic leukemia without active-disease features is generally observed rather than treated immediately. Treatment depends on clinically meaningful progression, including worsening marrow failure, symptomatic or progressive bulky disease, or disease-related constitutional symptoms. An elevated lymphocyte count alone does not establish a treatment indication. Observation includes planned clinical and laboratory reassessment and avoids toxicity before a demonstrated need for therapy.
Apply it
A patient has stable hemoglobin and platelets, small painless nodes, and no constitutional symptoms. Choose observation rather than starting treatment solely because the absolute lymphocyte count is high.
Common pitfall: Observation is an active management strategy. It should neither become automatic immediate treatment for an isolated count nor neglect of new symptoms or progressive cytopenias.
13.Which findings suggest Richter transformation in CLL?
Richter transformation is development of an aggressive lymphoma in a patient with CLL, most often diffuse large B-cell lymphoma. Rapid focal nodal enlargement, new constitutional symptoms, rising lactate dehydrogenase, or disproportionate deterioration should raise suspicion. Tissue biopsy is necessary because infection or ordinary CLL progression can produce overlapping findings. Imaging can identify an appropriate biopsy site but cannot replace histologic confirmation.
Apply it
Previously indolent CLL changes abruptly with a rapidly enlarging unilateral node, fever, and a substantial LDH rise. Obtain representative tissue rather than assuming routine progression.
Common pitfall: Empirically escalating CLL therapy can miss aggressive lymphoma or infection. Peripheral-blood findings do not establish the histology of a new, clinically aggressive nodal lesion.
14.Which imaging findings establish myeloma-related bone disease?
Clear osteolytic destruction at least 5 mm on CT, including the CT component of PET/CT, can satisfy the myeloma bone-lesion criterion even when radiographs are negative. When clonal marrow plasma cells are below 10%, more than one bone lesion is required to distinguish myeloma from solitary plasmacytoma with minimal marrow involvement. Increased PET uptake alone is insufficient without underlying lytic destruction. Osteoporosis or compression fractures without lytic lesions also do not independently qualify.
Apply it
A patient has a biopsy-proven plasmacytoma, 6% clonal marrow plasma cells, and one destructive bone lesion without other defining events. Assess for solitary plasmacytoma with minimal marrow involvement; the single lesion does not establish the multiple-bone-lesion distinction required at this marrow level.
Common pitfall: The separate MRI biomarker requires more than one focal lesion, each at least 5 mm. Do not interchange PET uptake, CT destruction, and MRI focal lesions or overlook the exception for marrow involvement below 10%.
15.Why must suspected acute promyelocytic leukemia be treated before genetic confirmation?
Suspected acute promyelocytic leukemia is an emergency because its coagulopathy can cause fatal hemorrhage before definitive treatment. Start all-trans retinoic acid promptly while urgently testing for PML::RARA and correcting coagulopathy. Provide platelets, fibrinogen replacement, and plasma as indicated with frequent laboratory reassessment. ATRA promotes differentiation; definitive therapy uses a risk-adapted ATRA-based combination, often including arsenic trioxide. These actions follow the [European LeukemiaNet APL recommendations](https://www.leukemia-net.org/sites/leukemia-net/content/e58/e480/e7392/e7396/e11507/SanzMAetal2019_Blood.Managementofacutepromyelocyticleukemia-updatedrecommendationsfromanexpertpaneloftheEuropeanLeukemiaNet.pdf).
Apply it
Bleeding, thrombocytopenia, low fibrinogen, and abnormal promyelocytes with bundled Auer rods justify immediate hematology-led ATRA and blood-product support while molecular confirmation proceeds.
Common pitfall: Do not wait for the fusion result before starting ATRA when suspicion is strong. Avoid unnecessary invasive procedures during active coagulopathy. New respiratory distress, weight gain, or hypotension during differentiation therapy raises concern for differentiation syndrome and warrants prompt corticosteroid treatment.
Medical Oncology Certification Examination Expanded Blueprint
16.How do MGUS and biomarker-defined active myeloma differ?
Non-IgM MGUS generally requires serum monoclonal protein below 3 g/dL, fewer than 10% clonal marrow plasma cells, and no attributable myeloma-defining injury or amyloidosis. Active myeloma requires an appropriate clonal disorder plus a defining event. Biomarkers can establish active disease before CRAB injury: at least 60% clonal marrow plasma cells; an involved-to-uninvolved free light-chain ratio at least 100 with involved concentration at least 100 mg/L; or more than one MRI focal lesion, each at least 5 mm.
Apply it
A patient with a small monoclonal protein, 6% clonal marrow plasma cells, and no attributable injury or defining event fits MGUS. A patient with 65% clonal marrow plasma cells meets an active-myeloma biomarker even with normal calcium, hemoglobin, and renal function.
Common pitfall: Apply each complete criterion. A qualifying free light-chain ratio requires the specified involved-chain concentration. Anemia or renal impairment from another illness does not automatically establish myeloma, while absence of CRAB injury does not negate a defining biomarker.
NCI: Plasma Cell Neoplasms Treatment (PDQ) · IMWG Criteria for the Diagnosis of MM | Inl Myeloma Fn
17.When can PD-1 blockade enter a lymphoma treatment decision?
Lymphoma subtype and previous treatment determine whether checkpoint therapy is appropriate. Pembrolizumab is indicated for adults with relapsed or refractory classical Hodgkin lymphoma. Its labeling separately permits treatment of refractory primary mediastinal large B-cell lymphoma or disease relapsing after at least two prior treatment lines. The latter indication carries a caution against use when urgent cytoreduction is required.
Apply it
For an adult with confirmed relapsed classical Hodgkin lymphoma, include PD-1 blockade among options while reviewing prior treatment, transplant plans, autoimmune risk, and goals.
Common pitfall: Eligibility in one lymphoma subtype does not establish eligibility in every lymphoma. A treatment's labeled activity also does not guarantee sufficiently rapid reduction of a threatening tumor burden.
18.How does BCR::ABL1 drive CML treatment selection?
The BCR::ABL1 fusion produces a constitutively active tyrosine kinase that drives chronic myeloid leukemia. It provides a diagnostic molecular feature and a target for tyrosine kinase inhibitors. The fusion commonly results from the Philadelphia chromosome translocation. Inhibitor selection considers disease characteristics, resistance, comorbidities, and toxicity because drugs sharing the target do not have identical mutation coverage or adverse effects.
Apply it
Persistent leukocytosis, basophilia, and splenomegaly with confirmed BCR::ABL1 support CML. Connect the fusion to targeted treatment rather than addressing the blood count alone.
Common pitfall: Normal blood counts do not establish molecular eradication. Diagnosis should identify the transcript type because unusual transcripts can require a tailored assay for subsequent monitoring.
NCI: Chronic Myeloid Leukemia Treatment (PDQ) · Apperley_J.etal_Leukemia2025.2025EuropeanLeukemiaNetrecommendationsforthemanagementofchronicmyeloidleukemia.pdf
19.How are CML molecular milestones and response depth interpreted?
Quantitative BCR::ABL1 on the International Scale measures residual molecular disease. Favorable milestones are no more than 10% at three months, 1% at six months, and 0.1% at twelve months. Major molecular response is no more than 0.1%; MR4 is no more than 0.01%, with adequate assay sensitivity. Interpret serial results alongside adherence, interruptions, interactions, toxicity, and treatment goals.
Apply it
At twelve months, a result of 0.08% meets major molecular response but not MR4. An unexpected subsequent rise warrants confirmation and assessment of its cause.
Common pitfall: A single value should not automatically dictate a treatment switch. Review the trajectory and investigate unexplained rises, including possible resistance, rather than equating blood-count normalization with molecular response.
Thoracic Cancer11.5%
20.Why should molecular testing precede metastatic NSCLC treatment selection?
Actionable oncogenic drivers can determine systemic treatment for metastatic non-small cell lung cancer. Molecular assessment should inform initial selection because a matched targeted strategy may be preferable to an empiric immunotherapy approach. Histology, specimen adequacy, and clinical urgency shape testing. PD-L1 expression answers a different question and does not substitute for identifying sensitizing EGFR alterations, ALK rearrangements, or other actionable drivers.
Apply it
A stable patient has metastatic lung adenocarcinoma and high PD-L1 expression while molecular results remain pending. Complete driver assessment before selecting treatment from PD-L1 alone.
Common pitfall: High PD-L1 expression does not erase an actionable driver. Smoking history and demographic associations also cannot reliably exclude a targetable alteration in an individual tumor.
21.Which EGFR findings support an EGFR-directed treatment strategy?
EGFR-directed treatment depends on the specific alteration rather than the presence of any change in the gene. Common sensitizing alterations include exon 19 deletions and exon 21 L858R. Other variants have different sensitivities and require separate interpretation. In metastatic disease with a sensitizing alteration, an appropriate EGFR-directed strategy can take precedence over selection based on PD-L1 expression.
Apply it
A metastatic lung adenocarcinoma carries an exon 19 deletion. Recognize the sensitizing driver and consider appropriate EGFR-directed treatment, incorporating CNS disease, tolerability, and treatment setting.
Common pitfall: An unspecified report of an EGFR mutation is insufficient for precise drug selection. Clarify the actual variant rather than assuming that all EGFR alterations respond similarly.
22.How does an ALK rearrangement change metastatic NSCLC care?
An ALK rearrangement creates an oncogenic fusion kinase that can be targeted with ALK inhibitors. In metastatic NSCLC, the finding changes systemic treatment selection. Intracranial activity matters because brain disease is clinically important in this population. A validated tumor result establishes the target; demographic associations may prompt suspicion but cannot replace biomarker assessment. Drugs sharing an ALK target differ in CNS activity and toxicity.
Apply it
A patient with confirmed ALK-positive metastatic lung adenocarcinoma has small asymptomatic brain metastases. Consider an ALK inhibitor with CNS activity while coordinating local-treatment decisions.
Common pitfall: Selecting therapy from age or smoking history alone can miss actionable disease. A presumed clinical phenotype is weaker evidence than a validated molecular finding.
23.What distinguishes limited-stage from extensive-stage SCLC?
The traditional limited-stage designation describes small cell lung cancer within a distribution that can be encompassed by a tolerable thoracic radiation field. Extensive-stage disease extends beyond that setting, including distant metastases. The distinction guides whether definitive thoracic chemoradiation forms the initial backbone. TNM staging remains informative, and borderline thoracic findings need careful multidisciplinary review rather than classification by lesion count alone.
Apply it
Disease in one lung and regional nodes, without distant spread and with a feasible radiation field, can represent limited-stage SCLC despite nodal involvement.
Common pitfall: Limited-stage does not mean node-negative or tiny disease. Conversely, a compact thoracic mass does not make disease limited-stage when distant metastases are present.
24.Why is systemic treatment central in extensive-stage SCLC?
Small cell lung cancer tends to disseminate early, so extensive-stage disease requires systemic treatment rather than management of the thoracic mass alone. Platinum-etoposide with an appropriate checkpoint inhibitor is an established initial approach for eligible patients. Local treatment can have selected roles but does not replace systemic control. Performance status, organ function, symptoms, and contraindications determine whether a particular combination is suitable.
Apply it
Newly diagnosed SCLC with liver metastases requires a systemic-treatment assessment. Evaluate eligibility for chemotherapy and immunotherapy rather than proposing thoracic surgery as definitive management.
Common pitfall: A striking thoracic mass can distract from distant spread. Local shrinkage or symptom improvement does not establish control of disease throughout the body.
25.How should progression on targeted NSCLC therapy be evaluated?
Progression during targeted therapy can reflect acquired molecular resistance, histologic transformation, or limited escape at one site despite broader disease control. Distribution and tempo therefore matter. Repeat tissue or plasma assessment can identify resistance mechanisms when clinically useful. Tissue also permits histologic evaluation. A negative plasma result does not exclude an alteration because tumor DNA shedding varies.
Apply it
A patient benefiting from an EGFR inhibitor develops systemic progression. Review imaging and obtain appropriate resistance testing, considering tissue when transformation is possible.
Common pitfall: The original driver does not fully explain every later change in behavior. A negative liquid biopsy may be noninformative and should be interpreted against tissue feasibility and the clinical pattern.
26.How should suspected checkpoint-inhibitor pneumonitis change immediate care?
New dyspnea, hypoxemia, and pulmonary infiltrates during checkpoint treatment require withholding treatment and urgent evaluation. Assess severity and investigate infection, pulmonary embolism, progression, and other cardiopulmonary causes. Symptomatic immune-mediated pneumonitis requires treatment interruption and severity-based corticosteroid management. Pembrolizumab labeling specifies withholding for grade 2 pneumonitis and permanent discontinuation for grade 3 or 4 disease.
Apply it
A patient receiving pembrolizumab develops low oxygen saturation and bilateral infiltrates. Withhold treatment, arrange urgent assessment and supportive care, and manage suspected toxicity according to severity.
Common pitfall: Continuing treatment while awaiting the next routine appointment can worsen serious toxicity. Conversely, labeling every infiltrate immune-mediated can delay necessary investigation and treatment of infection.
NCI: Non-Small Cell Lung Cancer Treatment (PDQ) · DailyMed - KEYTRUDA- pembrolizumab injection, powder, lyophilized, for solution KEYTRUDA- pembrolizumab injection, solution
Breast Cancer13.5%
27.How does ER positivity guide breast-cancer treatment?
Estrogen-receptor positivity identifies a tumor potentially dependent on estrogen signaling and makes endocrine therapy relevant. Tamoxifen blocks receptor signaling; aromatase inhibitors reduce estrogen synthesis in appropriate hormonal settings. Treatment also depends on stage, HER2 status, prior therapy, and disease tempo. In advanced disease, immediately threatening organ dysfunction can change urgency even when hormone receptors are present.
Apply it
A patient has ER-positive metastatic breast cancer with slowly progressive bone disease and no organ-threatening dysfunction. Consider an endocrine-based strategy using menopausal status and treatment history to guide selection.
Common pitfall: ER positivity does not guarantee equal endocrine responsiveness in every situation. Prior resistance and immediate organ risk remain important, and metastatic disease alone does not automatically require chemotherapy.
NCI: Hormone Therapy for Breast Cancer · NCI: Breast Cancer Treatment (PDQ)
28.Why does an aromatase inhibitor require ovarian suppression before menopause?
Aromatase inhibitors block peripheral estrogen synthesis but do not reliably suppress functioning ovaries. Ovarian feedback can maintain estrogen production, making an aromatase inhibitor alone inadequate before menopause. Effective ovarian suppression or ablation is therefore required when this strategy is chosen. Chemotherapy-associated amenorrhea does not necessarily establish permanent menopause because ovarian function may recover.
Apply it
A patient with functioning ovaries is offered an adjuvant aromatase inhibitor for ER-positive breast cancer. Pair it with effective ovarian suppression or choose another suitable endocrine strategy.
Common pitfall: Absent menstrual bleeding is not sufficient proof of permanent ovarian failure. Monitoring alone does not replace the suppression required for an aromatase-inhibitor strategy in a premenopausal patient.
29.What should follow a HER2 IHC 2+ result?
HER2 immunohistochemistry scored 2+ is equivocal and requires further evaluation using in situ hybridization or the recommended validated algorithm. IHC 2+ alone establishes neither amplification nor conventional HER2-positive status. The final interpretation integrates IHC and ISH findings. Eligibility for particular antibody-drug conjugates in defined settings is a related but separate question from conventional HER2 classification.
Apply it
An invasive tumor is ER-negative, PR-negative, and HER2 IHC 2+. Complete HER2 assessment before calling it triple-negative or conventionally HER2-positive.
Common pitfall: Both premature positive and premature negative classifications can misdirect treatment. Estrogen-receptor results cannot resolve equivocal HER2 testing because the assays measure different biological features.
ASCO–CAP HER2 Breast Testing Guideline Update: Summary of Recommendations
30.Which LVEF changes meet labeled criteria for withholding trastuzumab?
Herceptin labeling directs withholding for at least four weeks for an absolute LVEF decrease of at least 16 percentage points, or an LVEF below the institutional normal limit with an absolute decrease of at least 10 points. Trastuzumab can cause asymptomatic dysfunction or clinical heart failure. Baseline and interval measurements allow application of these criteria.
Apply it
LVEF falls from 65% to 48%, with a lower normal limit of 53%. The 17-point decrease meets withholding criteria even without symptoms. Evaluate dysfunction and arrange reassessment.
Common pitfall: Use absolute percentage-point changes rather than relative percentage decreases. Absence of dyspnea does not override the criteria, while every minor decline does not automatically require permanent discontinuation.
NCI: Breast Cancer Treatment (PDQ) · These highlights do not include all the information needed to use HERCEPTIN safely and effectively. See full prescribing information for HERCEPTIN. HERCEPTIN® (trastuzumab) for injection, for intravenous use Initial U.S. Approval: 1998
31.What distinguishes DCIS from invasive breast carcinoma?
Ductal carcinoma in situ consists of malignant epithelial cells confined within ducts without invasion into surrounding stroma. Management emphasizes local control and prevention of invasive recurrence rather than routine systemic chemotherapy. Endocrine therapy may reduce subsequent breast events in selected hormone-receptor-positive disease. Possible occult invasion influences nodal planning, particularly when mastectomy would make later sentinel-node mapping difficult.
Apply it
A patient with DCIS on core biopsy plans mastectomy. Discuss whether sentinel-node assessment should accompany surgery because the definitive specimen could reveal invasion.
Common pitfall: A limited biopsy cannot guarantee that invasion is absent throughout the lesion. Nevertheless, applying invasive-cancer chemotherapy pathways to established pure DCIS overstates its biology.
32.Why can invasive lobular carcinoma be difficult to define clinically?
Invasive lobular carcinoma often grows diffusely with reduced cellular cohesion. It may be less conspicuous as a discrete mass, and initial examination or imaging can underestimate its extent. Multifocality and bilateral disease are relevant considerations. Histology informs assessment, but systemic treatment still depends on stage and biomarkers rather than lobular subtype alone.
Apply it
Examination suggests a larger area of disease than the initial imaging focus in biopsy-proven lobular carcinoma. Reconcile the discrepancy before finalizing local treatment and surgical counseling.
Common pitfall: A small measured focus may underestimate infiltrative disease. Conversely, lobular histology does not independently dictate a universal operation or systemic regimen without consideration of extent, receptor status, and patient circumstances.
33.Which findings distinguish inflammatory breast cancer from other locally advanced presentations?
Rapid breast erythema, edema, warmth, or peau d'orange warrants urgent assessment for inflammatory breast cancer, even without a dominant mass. Conventional diagnostic criteria require rapid symptom development over no more than six months, erythema involving at least one-third of the breast, and pathological confirmation of invasive carcinoma. Diagnosis combines the clinical pattern with tissue evidence; suspicious skin changes alone do not establish it. Dermal lymphatic tumor emboli support the diagnosis but are not mandatory.
Apply it
Erythema and peau d'orange develop over eight weeks across half the breast, and core biopsy confirms invasive carcinoma. The presentation meets the conventional discriminators even if skin biopsy does not show dermal lymphatic emboli. Coordinate staging and multimodality treatment.
Common pitfall: Do not label every neglected locally advanced tumor with skin involvement inflammatory. Conversely, repeated antibiotics or a negative skin sample should not delay evaluation of a convincing rapid diffuse presentation.
International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment - PMC · NCI: Breast Cancer Treatment (PDQ)
34.How should a new breast-cancer recurrence be reassessed?
When feasible, biopsy of suspected recurrence establishes the diagnosis and permits reassessment of ER, PR, and HER2. Biomarkers can differ from the original tumor because of biological evolution, treatment selection, or sampling variation. A new lesion can also represent a different malignancy or benign process. Treatment should integrate current disease characteristics, distribution, prior therapy, and goals.
Apply it
Years after ER-positive breast cancer treatment, a patient develops a liver lesion. Obtain tissue when feasible and reassess receptors before automatically repeating an earlier systemic strategy.
Common pitfall: Historical biomarkers provide context but do not guarantee current biology. Assuming that every new lesion is breast-cancer recurrence can miss another diagnosis requiring different care.
Genitourinary Cancer12%
35.How should elevated AFP change interpretation of seminoma?
Pure seminoma does not produce alpha-fetoprotein. A meaningful AFP elevation despite seminoma histology raises concern for an unrecognized nonseminomatous component after other explanations, such as liver disease or a stable nonmalignant elevation, are considered. This distinction changes classification and management. Beta-hCG can be elevated in seminoma, so the markers have different diagnostic implications.
Apply it
AFP is clearly elevated and rising after an orchiectomy reported as seminoma, without a hepatic explanation. Review pathology and assess for nonseminomatous disease.
Common pitfall: Do not apply the AFP rule to beta-hCG. Conversely, a mild stable AFP abnormality requires interpretation rather than automatic assignment of malignant marker production without considering alternative causes.
36.How should germ cell tumor markers decline after orchiectomy?
AFP has a serum half-life of approximately five to seven days; hCG has a half-life of approximately one to three days. Elevated preoperative markers can therefore take several weeks to normalize. Interpret serial postoperative values against the marker's expected clearance. A plateau, rise, or slower-than-expected decline suggests continued production and requires assessment for residual disease and alternative causes. Marker normalization does not exclude metastatic disease.
Apply it
Using a seven-day AFP half-life, a preoperative AFP of 800 ng/mL would decline to approximately 400 at seven days and 200 at fourteen days if production ceased. Using a two-day hCG half-life, 160 IU/L would fall to approximately 80 after two days and 40 after four. A sustained plateau or rise is inconsistent with these clearance examples.
Common pitfall: The examples illustrate ranges rather than fixed deadlines. Early postoperative positivity can reflect normal clearance, while normalized markers cannot replace staging imaging because some metastatic components do not secrete these markers.
Diagnostic Evaluation - EAU Guidelines on Testicular Cancer - Uroweb · NCI: Testicular Cancer Treatment (PDQ)
37.Why is metastatic hormone-sensitive prostate cancer often intensified?
Androgen deprivation suppresses signaling that drives most prostate cancers. Eligible patients with metastatic hormone-sensitive disease can benefit from additional systemic treatment, such as an androgen-receptor-pathway agent and, in selected patients, a chemotherapy-containing strategy. Fitness, disease burden, comorbidity, and goals guide selection. Distant metastasis alone does not establish castration resistance.
Apply it
A fit patient presents with untreated metastatic prostate cancer. Discuss androgen deprivation with an evidence-based intensification option rather than assuming that deprivation alone is appropriate for every patient.
Common pitfall: Castration-resistant disease requires progression despite an adequately suppressed testosterone environment. Calling newly metastatic disease resistant before that assessment confuses disease states and the rationale for treatment.
38.What explains abiraterone-associated hypertension and hypokalemia?
Abiraterone inhibits CYP17-mediated steroid synthesis, reducing androgen and cortisol production. Increased ACTH drive can promote mineralocorticoid precursor accumulation, causing hypertension, hypokalemia, and fluid retention. The accompanying glucocorticoid helps suppress this drive. Monitor blood pressure, potassium, fluid status, and hepatic function. New edema or weakness requires assessment rather than automatic attribution to cancer progression.
Apply it
A patient taking abiraterone develops edema, rising blood pressure, and low potassium after missing prednisone. Evaluate drug-related mineralocorticoid effects, cardiovascular status, and adherence.
Common pitfall: Potassium replacement alone may leave the underlying physiology unaddressed. Abiraterone inhibits steroid synthesis; it is not simply a direct androgen-receptor blocker or glucocorticoid-receptor agonist.
NCI: Prostate Cancer Treatment (PDQ) · zytiga-epar-product-information_en.pdf
39.How do advanced and postoperative renal cell cancer treatment decisions differ?
Advanced renal cell carcinoma and recurrence prevention after nephrectomy are different treatment settings. Pembrolizumab with axitinib or with lenvatinib has a first-line indication for advanced RCC. Pembrolizumab monotherapy has an adjuvant indication after nephrectomy, or nephrectomy plus resection of metastases, in patients at intermediate-high or high recurrence risk. An adjuvant decision therefore requires recurrence-risk assessment rather than automatic treatment of every resected renal cancer.
Apply it
For untreated advanced RCC, discuss an appropriate systemic combination and review blood pressure, hepatic function, and tolerability. For a patient without measurable disease after nephrectomy, establish whether pathological recurrence risk supports an adjuvant discussion.
Common pitfall: Do not transfer an advanced-disease combination automatically into the postoperative setting. Hypertension, diarrhea, proteinuria, and hepatic toxicity are relevant when assessing and monitoring these combinations; PD-L1 CPS thresholds from other cancers do not define these RCC indications.
DailyMed - KEYTRUDA- pembrolizumab injection, powder, lyophilized, for solution KEYTRUDA- pembrolizumab injection, solution · Medical Oncology Certification Examination Expanded Blueprint
40.Which bladder-wall layer defines muscle-invasive urothelial cancer?
Invasion into muscularis propria, or detrusor muscle, defines muscle-invasive bladder cancer and corresponds to at least T2 disease. Lamina propria invasion is T1 and remains non-muscle-invasive despite its seriousness. Adequate sampling is essential because absence of detrusor in a specimen can leave deeper invasion uncertain. This boundary changes staging and consideration of definitive treatment.
Apply it
A specimen shows high-grade carcinoma invading lamina propria but contains no muscularis propria. Recognize T1 invasion in the sampled tissue and address staging adequacy.
Common pitfall: Lamina propria is not detrusor. Absence of muscularis propria in the specimen also does not prove that deeper invasion is absent elsewhere in the tumor.
41.Which features favor trimodality bladder preservation?
Trimodality treatment combines maximal transurethral tumor resection with concurrent chemoradiation. Favorable features include a solitary tumor, feasible complete transurethral resection, useful baseline bladder function, and absence of extensive carcinoma in situ or hydronephrosis. These features improve suitability and expected outcomes; they are selection factors rather than a universal list of absolute exclusions. Tumor extent, fitness, preferences, and the ability to complete treatment and follow-up also matter.
Apply it
A patient with localized muscle-invasive disease, a completely resectable solitary tumor, good bladder function, and no hydronephrosis is a favorable candidate for multidisciplinary assessment. Discuss cystectomy alongside bladder preservation, including planned cystoscopic surveillance and salvage cystectomy for persistent or recurrent invasive disease.
Common pitfall: Retaining the bladder after limited resection and observation is not trimodality therapy. Absence of one favorable feature requires individualized assessment, while invasive failure requires timely salvage evaluation rather than indefinite surveillance.
Gynecologic Cancer5.5%
42.What constitutes definitive treatment for locally advanced cervical cancer?
Definitive treatment commonly combines external-beam radiation, brachytherapy, and concurrent cisplatin-based chemotherapy. Brachytherapy is an essential component of the standard radiation approach, rather than an optional replacement by chemotherapy alone. The [NCI cervical treatment summary](https://www.cancer.gov/types/cervical/hp/cervical-treatment-pdq) describes this combined strategy. Pembrolizumab also has a chemoradiation-combination indication for FIGO 2014 stage III–IVA disease; this differs from its CPS-selected recurrent or metastatic indications.
Apply it
A fit patient has cervical cancer extending to the pelvic sidewall without distant metastasis. Plan definitive chemoradiation including brachytherapy and assess eligibility for the stage-specific pembrolizumab combination.
Common pitfall: Do not omit brachytherapy merely because systemic therapy is added. Keep the staging edition and treatment setting explicit: the CPS requirement for pembrolizumab in persistent, recurrent, or metastatic cervical cancer should not be imported into its stage III–IVA chemoradiation indication.
DailyMed - KEYTRUDA- pembrolizumab injection, powder, lyophilized, for solution KEYTRUDA- pembrolizumab injection, solution · Medical Oncology Certification Examination Expanded Blueprint
43.How do repair defects and disease setting guide ovarian-cancer treatment?
PARP participates in single-strand DNA damage repair. Its inhibition can cause replication-associated double-strand damage that BRCA-deficient homologous recombination cannot adequately repair, producing synthetic lethality. BRCA-associated disease and broader homologous recombination deficiency can inform maintenance after platinum response, but eligibility depends on the particular drug, treatment line, prior exposure, and response. A pathogenic tumor BRCA finding may be somatic or inherited and requires separate germline assessment. Advanced ovarian cancer also requires sequencing decisions: primary cytoreduction when an appropriate result is likely with acceptable morbidity, or neoadjuvant chemotherapy followed by interval surgery when immediate surgery is unsuitable.
Apply it
A patient with extensive epithelial ovarian cancer receives neoadjuvant therapy because satisfactory immediate cytoreduction is unlikely. After platinum response and surgical reassessment, evaluate maintenance using BRCA/HRD findings, the specific indication, and toxicity. Arrange germline assessment for a pathogenic tumor BRCA variant.
Common pitfall: HRD is not permission to use any PARP inhibitor at any stage, and restored repair capacity can contribute to resistance. Tumor sequencing does not establish inheritance; a negative family history does not exclude it, and a variant of uncertain significance is not equivalent to a pathogenic variant.
NCI: Ovarian Epithelial, Fallopian Tube and Primary Peritoneal Cancer Treatment (PDQ) · NCI: BRCA Gene Changes—Cancer Risk and Genetic Testing
44.How does mismatch-repair status guide advanced endometrial cancer therapy?
Treatment setting and MMR status must be interpreted together. Pembrolizumab with carboplatin and paclitaxel, followed by pembrolizumab, has an indication for primary advanced or recurrent endometrial carcinoma regardless of MMR status. After prior systemic therapy, pembrolizumab monotherapy is an option for qualifying MSI-high/dMMR disease when curative surgery or radiation is unsuitable. Pembrolizumab with lenvatinib has a separate indication for qualifying pMMR or non-MSI-high disease after prior systemic therapy.
Apply it
A patient with advanced pMMR endometrial cancer progresses after systemic therapy and has no curative local option. Assess pembrolizumab-lenvatinib rather than assuming that pembrolizumab monotherapy has the same biomarker eligibility.
Common pitfall: Do not apply the post-treatment monotherapy restriction to the initial chemotherapy-combination indication. Confirm prior therapy, local-treatment possibilities, and toxicity risk; lenvatinib combinations require attention to hypertension, proteinuria, diarrhea, and other adverse effects.
DailyMed - KEYTRUDA- pembrolizumab injection, powder, lyophilized, for solution KEYTRUDA- pembrolizumab injection, solution · Medical Oncology Certification Examination Expanded Blueprint
Gastrointestinal Cancer13.5%
45.How do RAS alterations affect anti-EGFR treatment and matched KRAS G12C combinations?
Activating KRAS or NRAS alterations sustain signaling downstream of EGFR and predict resistance to conventional cetuximab or panitumumab strategies without matched KRAS inhibition. KRAS G12C creates a specific combination-treatment exception. FDA granted accelerated approval to adagrasib plus cetuximab for eligible adults with KRAS G12C colorectal cancer after fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
Apply it
Distinguish KRAS G12D disease being considered for cetuximab alone from previously treated KRAS G12C disease potentially eligible for matched combination therapy.
Common pitfall: Do not convert conventional anti-EGFR resistance into a blanket exclusion of combinations targeting the matched KRAS variant. Confirm the exact alteration and required treatment history; EGFR expression alone is insufficient.
NCI: Colon Cancer Treatment (PDQ) · FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C-mutated colorectal cancer | FDA
46.How does mismatch-repair deficiency affect metastatic colorectal treatment?
Defective mismatch repair allows replication errors to accumulate, often producing microsatellite instability and numerous tumor alterations. In metastatic colorectal cancer, dMMR or MSI-high status identifies clinically important checkpoint-therapy sensitivity. This differs from the treatment question answered by RAS testing. MMR or MSI findings can also prompt hereditary-risk evaluation, although a deficient tumor does not by itself establish germline Lynch syndrome.
Apply it
A newly diagnosed metastatic colon cancer has confirmed mismatch-repair deficiency. Incorporate checkpoint therapy into treatment consideration and arrange the appropriate hereditary-risk assessment.
Common pitfall: RAS wild-type status does not establish immunotherapy sensitivity. Likewise, dMMR does not prove inherited susceptibility, and one molecular test cannot replace another that answers a different question.
NCI: Colon Cancer Treatment (PDQ) · DailyMed - KEYTRUDA- pembrolizumab injection, powder, lyophilized, for solution KEYTRUDA- pembrolizumab injection, solution
47.How do stage, recurrence risk, and toxicity guide colon-cancer adjuvant treatment?
Stage III colon cancer has regional nodal involvement without distant metastasis. After complete resection, suitable patients generally receive adjuvant chemotherapy to reduce microscopic residual disease and recurrence risk, often using an oxaliplatin-containing fluoropyrimidine regimen. Stage II lacks nodal involvement, so treatment is more selective: tumor extent, obstruction or perforation, nodal assessment, and MMR status matter. dMMR/MSI-high argues against routine fluoropyrimidine monotherapy. During oxaliplatin treatment, distinguish brief cold-triggered sensory symptoms from cumulative neuropathy persisting between cycles and impairing function.
Apply it
Three involved regional nodes support an adjuvant discussion despite clear margins and negative imaging. In lower-risk dMMR stage II disease, surveillance may be appropriate. If persistent numbness impairs buttoning or walking during treatment, reassess further oxaliplatin exposure against expected benefit.
Common pitfall: Negative scans cannot exclude microscopic disease. Do not apply the stage III treatment rule to every stage II tumor or dismiss persistent functional neuropathy as transient cold sensitivity. Regimen and duration require both recurrence-risk and tolerability assessment.
48.How does resectability change pancreatic adenocarcinoma treatment?
Pancreatic treatment planning distinguishes resectable, borderline resectable, locally advanced unresectable, and metastatic disease. Vascular relationships and the likelihood of a margin-negative operation matter, not tumor diameter alone. Borderline resectable disease commonly receives neoadjuvant treatment followed by reassessment. After resection, suitable patients receive adjuvant chemotherapy; modified FOLFIRINOX is an option for fit patients. Metastatic disease requires systemic and supportive treatment rather than curative pancreatic resection. See the [NCI pancreatic treatment summary](https://www.cancer.gov/types/pancreatic/hp/pancreatic-treatment-pdq).
Apply it
A pancreatic mass has no distant metastases but vascular involvement makes a margin-negative operation uncertain. Obtain specialist resectability review and consider neoadjuvant treatment rather than assuming that absence of metastases mandates immediate surgery.
Common pitfall: Locally advanced unresectable disease is not synonymous with distant metastasis. CA 19-9 has limited specificity, and a normal result does not exclude recurrence; marker changes cannot replace imaging and clinical assessment.
Medical Oncology Certification Examination Expanded Blueprint
49.Why must hepatocellular carcinoma assessment include hepatic reserve?
Hepatocellular carcinoma treatment depends on tumor extent, performance status, and underlying liver function. A solitary technically removable tumor may still be unsuitable for resection when cirrhosis or portal hypertension creates excessive risk. Transplantation or local ablation can be relevant for selected early disease. For unresectable disease, systemic options require assessment of hepatic reserve and contraindications. Atezolizumab-bevacizumab evidence includes patients with Child-Pugh A liver function and excludes untreated or inadequately treated high-risk varices. See the [NCI liver treatment summary](https://www.cancer.gov/types/liver/hp/adult-liver-treatment-pdq).
Apply it
Before selecting bevacizumab-containing treatment for unresectable HCC, assess liver function, portal-hypertension complications, and variceal bleeding risk rather than considering tumor burden alone.
Common pitfall: Evidence in compensated liver disease cannot be assumed to apply unchanged to decompensated cirrhosis. Technical operability does not establish physiological suitability for resection, and systemic treatment should not bypass assessment of potentially curative local options.
Medical Oncology Certification Examination Expanded Blueprint
50.Why is chemoradiation central to localized anal squamous cancer?
For most localized anal canal squamous carcinomas, definitive chemoradiation offers curative treatment while preserving the sphincter. Radiation with a fluoropyrimidine and mitomycin is an established approach. Histology and exact location matter because anal adenocarcinoma and selected small anal-margin lesions may follow different pathways. Routine primary abdominoperineal resection is therefore not the default for anal canal squamous disease.
Apply it
A fit patient has nonmetastatic anal canal squamous carcinoma. Discuss definitive chemoradiation and its organ-preserving intent rather than routine immediate radical surgery.
Common pitfall: Do not generalize this pathway to every anal-region or rectal malignancy. Chemotherapy alone also does not replace the definitive radiation component of the established combined strategy.
51.When should residual anal cancer prompt salvage surgery?
Anal squamous cancers can continue regressing after chemoradiation. The [ACT II response-timing analysis](https://pubmed.ncbi.nlm.nih.gov/28209296/) assessed response at 11, 18, and approximately 26 weeks from the start of chemoradiation and documented later complete responses among early incomplete responders. A regressing lesion without progression warrants serial reassessment. Biopsy-proven persistent or recurrent localized disease can warrant salvage abdominoperineal resection.
Apply it
At 11 weeks from treatment initiation, a lesion is smaller but still palpable without progression. Continue structured reassessment toward the later response window. An enlarging lesion or other evidence of progression requires prompt investigation rather than waiting automatically until week 26.
Common pitfall: The 26-week anchor starts with chemoradiation, not its completion, and is not a mandatory waiting period for progressive disease. Premature salvage can sacrifice sphincter preservation, while indefinite observation of viable persistent disease can delay necessary treatment.
52.Which treatment framework applies to unresectable advanced biliary tract cancer?
Locally advanced unresectable or metastatic biliary tract cancer requires systemic-treatment assessment rather than an assumption that curative surgery remains feasible. Pembrolizumab with gemcitabine and cisplatin is a labeled option. Establish diagnosis, distribution, fitness, organ function, and suitability for each component. This indication does not require the PD-L1 CPS threshold used in certain other cancers.
Apply it
A patient with confirmed metastatic cholangiocarcinoma and adequate fitness is considering initial therapy. Discuss a gemcitabine-cisplatin and checkpoint-inhibitor approach after reviewing contraindications and goals.
Common pitfall: Do not import biomarker requirements from another cancer's indication. A shared drug name does not make eligibility, combination partners, or evidence interchangeable across disease sites.
Skin Cancer, Sarcomas, and Unknown Primary Site7%
53.Which melanoma findings guide sentinel-node biopsy?
Sentinel-node biopsy assesses occult regional spread in clinically node-negative melanoma. Discuss it for T1b lesions: thickness 0.8–1.0 mm or ulceration below 0.8 mm. It usually has a staging role above 1 mm in appropriate candidates. Routine biopsy is generally omitted for uncomplicated T1a lesions below 0.8 mm without ulceration.
Apply it
Discuss sentinel-node assessment for a clinically node-negative 0.9-mm melanoma. Contrast this with a 0.5-mm nonulcerated lesion without additional concerning features.
Common pitfall: A normal nodal examination does not exclude microscopic spread. A clinically suspicious node requires direct diagnostic evaluation rather than treating sentinel-node biopsy as the routine method for investigating palpable disease.
54.Why combine BRAF and MEK inhibition in selected melanoma?
A BRAF V600 alteration can activate MAPK signaling. Combined BRAF and MEK inhibition blocks the pathway at two levels, improving disease control compared with BRAF inhibition alone and reducing some paradoxical pathway effects. The strategy requires an appropriate actionable alteration. Selection among targeted and immune approaches also depends on disease tempo, sites, previous therapy, and fitness.
Apply it
Metastatic melanoma has a confirmed BRAF V600 alteration. If choosing targeted treatment, assess a combined BRAF-MEK strategy rather than assuming that a BRAF inhibitor alone is sufficient.
Common pitfall: Any BRAF finding is not equivalent to an actionable V600 alteration. Mutation confirmation establishes a treatment option but does not eliminate consideration of immunotherapy or patient-specific circumstances.
55.Why does GIST genotype matter before targeted treatment?
Gastrointestinal stromal tumors often depend on KIT or PDGFRA signaling, but drug sensitivity varies by genotype. Molecular characterization therefore changes treatment selection. PDGFRA D842V is resistant to imatinib and has a distinct targeted option, avapritinib, in the relevant unresectable or metastatic setting. Diagnostic protein expression cannot substitute for variant-specific prediction of drug sensitivity.
Apply it
Unresectable GIST carries PDGFRA D842V. Evaluate avapritinib rather than routine imatinib, considering the disease setting, eligibility, and adverse-effect profile.
Common pitfall: KIT-positive staining does not identify the kinase mutation or guarantee imatinib sensitivity. A broad diagnosis of GIST should not obscure a genotype that predicts primary resistance to the proposed drug.
56.How is recurrence risk assessed after GIST resection?
GIST recurrence risk depends on tumor size, mitotic activity, primary site, and rupture. Negative margins do not make every tumor low risk. Adjuvant imatinib is considered for suitable high-risk tumors with a sensitive genotype, linking recurrence assessment with molecular prediction. Low-risk disease may avoid unnecessary toxicity, while a resistant genotype changes the adjuvant discussion.
Apply it
After complete resection, review size, mitoses, site, rupture, and genotype before selecting surveillance or adjuvant treatment rather than deciding from margins alone.
Common pitfall: Successful surgery does not guarantee negligible recurrence risk. Conversely, high recurrence risk cannot make an imatinib-resistant genotype sensitive, so anatomic risk and predictive biomarkers must both inform treatment.
Head, Neck, Thyroid, and Central Nervous System Malignancies6.5%
57.How do IDH status and 1p/19q codeletion classify adult glioma?
Adult diffuse glioma classification integrates molecular findings with histology. Oligodendroglioma requires an IDH mutation and whole-arm 1p/19q codeletion. IDH-mutant astrocytoma is distinct, and adult-type glioblastoma is IDH-wildtype. These differences affect prognosis and planning. Grade remains important, but similar microscopic appearances do not justify treating molecularly different tumors as the same diagnosis.
Apply it
A tumor resembles oligodendroglioma but lacks an IDH mutation. Resolve the integrated diagnosis with neuropathology rather than finalizing it from appearance alone.
Common pitfall: Partial chromosomal loss is not automatically the defining whole-arm codeletion. The molecular combination establishes tumor type but does not independently provide every finding needed to assign grade.
58.How does PD-L1 CPS inform first-line recurrent head and neck treatment?
For metastatic or unresectable recurrent head and neck squamous carcinoma, first-line pembrolizumab monotherapy requires PD-L1 CPS of at least 1 by an authorized test. Pembrolizumab with platinum and fluorouracil has a separate first-line indication without that CPS requirement. Symptoms, tempo, fitness, and need for tumor reduction still shape selection among eligible options.
Apply it
A patient with unresectable recurrent disease has CPS 0. Do not select monotherapy under the CPS-positive first-line indication; assess appropriate combination strategies and other options.
Common pitfall: CPS and lung-cancer tumor proportion score are different measures. Eligibility thresholds should remain attached to their cancer, treatment line, and exact regimen rather than transferred between indications.
59.How does MGMT promoter methylation inform glioma treatment discussions?
MGMT encodes a DNA-repair enzyme that can reverse damage caused by alkylating treatment. Promoter methylation is associated with reduced enzyme expression and greater sensitivity to temozolomide. It informs prognosis and treatment discussions in glioblastoma but does not guarantee benefit. Interpretation belongs alongside integrated tumor diagnosis, age, functional status, and the treatment setting.
Apply it
A patient asks whether MGMT methylation means temozolomide will certainly work. Explain the increased likelihood of benefit and the remaining uncertainty for an individual tumor.
Common pitfall: MGMT status does not replace IDH-based classification or establish oligodendroglioma. A predictive association should not be converted into a promise of response or interpreted without the broader clinical context.
60.How does prior platinum treatment change head and neck checkpoint eligibility?
Pembrolizumab has a separate single-agent indication for recurrent or metastatic head and neck squamous carcinoma progressing on or after platinum-containing chemotherapy. The stated indication does not impose the CPS threshold required for first-line monotherapy. Treatment history therefore changes the eligibility question, even when the tumor biomarker result is unchanged. Confirm the actual disease setting and progression history.
Apply it
A patient with recurrent metastatic disease and CPS 0 progresses after platinum chemotherapy. Review the post-platinum pembrolizumab indication rather than applying the first-line monotherapy threshold automatically.
Common pitfall: The same drug can have different requirements across treatment lines. Label eligibility also does not independently establish the best option when toxicity, clinical urgency, and competing therapies are considered.
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Use the official certification outline as the complete scope; these concepts provide selective coverage across its ten domains.
- Prioritize treatment decisions that integrate diagnosis, stage, biomarkers, prior treatment, functional status, and patient goals.
- Distinguish active-disease criteria from prognostic findings: a high lymphocyte count alone differs from a myeloma-defining biomarker.
- Separate tumor genotype from germline risk, equivocal receptor testing from final classification, and conventional anti-EGFR resistance from matched KRAS G12C combination eligibility.
- Recognize urgent neurologic, pulmonary, and leukemic complications and apply specific treatment-toxicity thresholds.
- Interpret response endpoints, serial molecular measurements, marker clearance, and treatment-line eligibility using their actual definitions.
- Connect major disease groups with their decisive treatment features: APL coagulopathy, RCC treatment setting, cervical brachytherapy, endometrial MMR status, pancreatic resectability, and hepatic reserve in HCC.
A practical preparation plan
1. Map the complete certification scope
Use the January 2026 CERT blueprint and expanded certification outline as your master checklist. Mark the topics covered here and identify additional required study in every domain.
2. Identify the finding that changes management
For each disease, name the decisive feature: active CLL, a myeloma-defining event, an actionable lung driver, functioning ovaries, detrusor invasion, or mismatch-repair deficiency.
3. Establish diagnosis and testing adequacy
Check histology, sampling, staging, and confirmatory biomarkers before selecting treatment. Explain specific uncertainties such as HER2 IHC 2+ or absence of detrusor muscle in a bladder specimen.
4. Complete the clinical questions
Choose an answer before reading the explanation. Classify errors by diagnosis, biomarker interpretation, treatment indication, toxicity recognition, or failure to use the decisive clinical cue.
5. Compare the closest alternatives
Explain why the correct decision fits and what would need to change for another option to become appropriate. Practise distinctions such as MGUS versus active myeloma and first-line versus post-platinum checkpoint eligibility.
6. Rehearse urgent care and communication
Practise immediate responses to suspected APL, cord compression, and symptomatic pneumonitis. Explain random assignment, concurrent palliative care, fertility timing, and goals-of-care recommendations in understandable language.
7. Use recall to verify reasoning
Answer each flashcard with both the fact and its clinical consequence. Review weak areas in the relevant clinical reference, then return to the full official outline to address unrepresented topics.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- Register, Prepare and Take Your Subspecialty Certification Exam: Medical Oncology
- Medical Oncology Blueprint for Certification Examination — January 2026
- ABIM Expanded Blueprints
- Medical Oncology Certification Examination Expanded Blueprint
- NCI: Clinical Trial Randomization
- NCI: Cancer Pain (PDQ), Health Professional Version
- NCI: Palliative Care in Cancer
- NCI: Female Fertility and Cancer
- NCI: Chronic Lymphocytic Leukemia Treatment (PDQ)
- NCI: Plasma Cell Neoplasms Treatment (PDQ)
- NCI: Chronic Myeloid Leukemia Treatment (PDQ)
- NCI: Non-Small Cell Lung Cancer Treatment (PDQ)
- NCI: Small Cell Lung Cancer Treatment (PDQ)
- NCI: Hormone Therapy for Breast Cancer
- ASCO–CAP HER2 Breast Testing Guideline Update: Summary of Recommendations
- NCI: Breast Cancer Treatment (PDQ)
- NCI: Testicular Cancer Treatment (PDQ)
- NCI: Prostate Cancer Treatment (PDQ)
- NCI: Bladder Cancer Treatment (PDQ)
- NCI: BRCA Gene Changes—Cancer Risk and Genetic Testing
- NCI: Ovarian Epithelial, Fallopian Tube and Primary Peritoneal Cancer Treatment (PDQ)
- NCI: Colon Cancer Treatment (PDQ)
- NCI: Anal Cancer Treatment (PDQ)
- NCI: Gastrointestinal Stromal Tumors Treatment (PDQ)
- NCI: Melanoma Treatment (PDQ)
- NCI: Central Nervous System Tumors Treatment (PDQ)
- FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C-mutated colorectal cancer | FDA
- IMWG Criteria for the Diagnosis of MM | Inl Myeloma Fn
- Apperley_J.etal_Leukemia2025.2025EuropeanLeukemiaNetrecommendationsforthemanagementofchronicmyeloidleukemia.pdf
- These highlights do not include all the information needed to use HERCEPTIN safely and effectively. See full prescribing information for HERCEPTIN. HERCEPTIN® (trastuzumab) for injection, for intravenous use Initial U.S. Approval: 1998
- DailyMed - KEYTRUDA- pembrolizumab injection, powder, lyophilized, for solution KEYTRUDA- pembrolizumab injection, solution
- Treatment - EAU Guidelines on Prostate Cancer - Uroweb
- Understanding Cancer Research Consent Forms - NCI
- Molecular Testing Guideline For The Selection Of Lung Cancer Patients For Treatment With TKI - CAP
- FDA approves durvalumab for limited-stage small cell lung cancer | FDA
- International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment - PMC
- Diagnostic Evaluation - EAU Guidelines on Testicular Cancer - Uroweb
- zytiga-epar-product-information_en.pdf
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.